CD52 antigen (Campath-1) is expressed in high density by lymphocytes and monocytes.
Campath-1H or
alemtuzumab, a human anti-CD52, has been shown to be effective in T-cell
malignancies; however, there is very limited information on CD52 expression in
T-cell lymphoma (TCL). This study retrospectively investigated 97 TCL cases by immunohistochemistry using
paraffin sections to elucidate the CD52 expression rates in various TCL sub-types. Fourteen cases of angioimmunoblastic
T-cell lymphoma (AITL) were excluded as there were no reliable criteria to differentiate whether the CD52-positive cells were neoplastic T-cells, which are usually small-sized, or the usually abundant, small-to-large residual/reactive B-cells in this
lymphoma sub-type. In the remaining 83
tumors, CD52 was expressed in 29 (35%)
tumors including 8/17 (47%) NK/
T-cell lymphomas, 14/35 (40%) unspecified peripheral TCLs and 4/18 (22%)
anaplastic large cell lymphomas. There was no statistical significance in CD52 expression in terms of patient age, gender, nodal vs extra-nodal presentation or
tumor sub-types. The authors recommend performing CD52 immunostaining for future clinical trials of
alemtuzumab on TCL patients and to correlate the staining results with treatment outcome.